

## 中山醫學大學生醫系傑出校友選拔推薦表

推薦類別：學術類 服務類 母系貢獻類 特殊類 填表日期：民國111年8月31日

被 推 薦 人	姓名	王竹安		性別	女	
	英文姓名	CHU AN WANG		生日	1980/03/20	
	畢業科系(級別)	87級				
	最高學歷	博士				
	經歷	<ul style="list-style-type: none"> <li>● 中山醫學大學生命科學系(學士)</li> <li>● 國立成功大學分子醫學所(碩士)</li> <li>● 美國科羅拉多大學丹佛分校(博士)</li> <li>● 美國科羅拉多大學丹佛分校(博士後研究員)</li> <li>● 國立成功大學基礎醫學所(博士後研究員)</li> </ul>				
	現職	國立成功大學基礎醫學研究所 助理教授				
	地址		聯絡電話	0988898014		
傑出事蹟	<ul style="list-style-type: none"> <li>● 2021- Outstanding Paper Award of the 31st Wang Ming-Ning Memorial Foundation Award</li> <li>● 2013-AACR-Aflac, Incorporated Scholar-in-Training Awards, 2013 AACR Advances in Breast Cancer Research</li> </ul>					
推薦單位	名稱	負責人簽名		通訊處及聯絡電話		
	生醫系	張文瑋		0911174148		
遴選委員會 審查意見						



附註：1. 「傑出事蹟」請以條列式詳舉具體事蹟，切勿繁文敘述。

2. 請於規定期限內，逕寄40201台中市南區建國北路一段110號 生物醫學科學學系。

3. 若以本系傑出系友選拔辦法第五條第四款方式推薦者，請書寫推薦人簽名表。

4. 本表若不敷使用，請自行影印。

## Curriculum Vitae

**Chu-An Wang, Ph.D.**

assistant professor

Department of Basic Medical Science, College of Medicine, National Cheng Kung University, Taiwan

### Research interest

1. Pancreatic cancer biology
2. Function and regulation of extracellular vesicle in cancer progression
3. Lipid metabolism in cancer progression
4. Tumor associated lymph-angiogenesis

### Publication

1. Chu-An Wang, Chien-Feng Li, Rho-Chi Huang, Yo-Hua Li, Jing-Ping Liou, Shaw-Jenq Tsai. Suppression of Extracellular Vesicle VEGF-C-mediated Lymphangiogenesis and Pancreatic Cancer Early Dissemination By a Selective HDAC1/2 Inhibitor. *Mol Cancer Ther.* 2021 Sep;20(9):1550-1560.
2. Wei-Che Tseng, Chi-Yuan Chen, Ching-Yuh Chern, Chu-An Wang, Wen-Chih Lee, Ying-Chih Chi, Shu-Fang Cheng, Yi-Tsen Kuo, Ya-Chen Chiu, Shih-Ting Tseng, Pei-Ya Lin, Shou-Jhen Liou, Yi-Chen Li, Chin-Chuan Chen. Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells. *Int J Mol Sci.* 2021 Apr 23;22(9):4422.
3. Wang CA and Shaw-Jenq Tsai. Regulation of lymphangiogenesis by extracellular vesicles in cancer metastasis. *Exp Biol Med (Maywood).* 2021 Jun 18;15353702211021022.
4. Wan-Ning Li, Kuei-Yang Hsiao, Chu-An Wang, Ning Chang, Pei-Ling Hsu, Chung-Hsien Sun, Shang-Rung Wu, Meng-Hsing Wu, Shaw-Jenq Tsai. Extracellular vesicle-associated VEGF-C promotes lymphangiogenesis and immune cells infiltration in endometriosis. *PNAS* October 13, 2020 117 (41) 25859-25868
5. Chu-An Wang, Yi-Hern Chang, Pei-Chi Hou, Yu-Jing Tai, Wan-Ning Li, Pei-Ling Hsu, Shang-Rung Wu, Wen-Tai Chiu, Chien-Feng Li, Yan-Shen Shan, Shaw-Jenq Tsai. DUSP2 regulates extracellular vesicle-VEGF-C secretion and pancreatic cancer early dissemination. *J Extracell Vesicles.* 2020 Apr 4;9(1):1746529.
6. Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, Ford HL. The Six1 oncoprotein represses translation of p53 via concomitant regulation of RPL26 and microRNA-27a. *Nat Commun.* 2015 Dec 21;6:10077.
7. Wang CA and Shaw-Jenq Tsai. The non-canonical role of vascular endothelial growth factor-C axis in cancer progression. *Exp Biol Med (Maywood).* 2015 Jun;240(6):718-24.
8. David J. Drasin, Anna L. Guarnieri, Deepika Neelakantan, Jihye Kim, Joshua H. Cabrera, Chu-An Wang, Vadym Zaberezhnyy, Pierluigi Gasparini, Luciano Cascione, Kay Huebner, Aik Choon Tan,

- Ford HL. TWIST1-induced microRNA-424 reversibly drives mesenchymal programming while inhibiting tumor initiation. *Cancer Res.* 2015 May 1;75(9):1908-21
9. Wang CA, Drasin DJ, Pham C, Jedlicka P, Zaberezhnyy V, Guney M, Li H, Nemenoff R, Costello J, Tan AC, Ford HL. Homeoprotein Six2 Promotes Breast Cancer Metastasis via Transcriptional and Epigenetic Control of E-Cadherin Expression. *Cancer Res.* 2014 Dec 15;74(24):7357-70.
  10. Wang CA, Harrell J, Iwanaga R, Jedlicka P, Ford HL. Vascular endothelial growth factor-C promotes breast cancer progression via a novel anti-oxidant mechanism that involves regulation of Superoxide dismutase 3. *Breast Cancer Res.* 2014 Oct 30;16(5):462.
  11. Ritsuko Iwanaga, Chu-An Wang, Douglas S. Micalizzi, Chuck J. Harrell, Paul Jedlicka, Carol Sartorius, Peter Kabos, Andrew P Bradford, Heide L. Ford. Six1 enhances tumor initiating cell activity and predicts poor prognosis in luminal breast cancers. *Breast Cancer Res.* 2012 Jul 5;14(4):R100.
  12. Wang CA, Jedlicka P, Patrick AN, Micalizzi DS, Lemmer KC, Deitsch E, Casás-Selves M, Harrell JC, Ford HL. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. *J Clin Invest.* 2012 May 1;122(5):1895-906.  
Research was highlighted as a short article at: Metastasis: SIX1 of the best. *Nat Rev Cancer.* 2012 May 24;12(5):316.
  13. Micalizzi DS, Wang CA, Farabaugh SM, Schiemann WP, Ford HL. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. *Cancer Res.* 2010 Dec 15;70(24):10371-80.
  14. W. Chen,S.-J. Tsai, C.-A. Wang, J.-C. Tsai, C.C. Zouboulis. Human sebocytes express prostaglandin E2 receptors EP2 and EP4 but treatment with prostaglandin E2 does not affect testosterone production. *Br J Dermatol.* 2009 Sep;161(3):674-7.
  15. Meng-Hsing Wu,\* Chu-An Wang,\* Chen-Chung Lin, Lei-Chin Chen, Wen-Chang Chang, and Shaw-Jenq Tsai. Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. *J Clin Endocrinol Metab.* 2005 Jan;90(1):286-95. (equal contribution first author)

## Invited talk

1. 2021-International Conference on Advanced Biomedical Sciences, Taichung, Taiwan. Nov 19-21. Session 2: Signal Transduction and Cancer. Title: Targeting DUSP2-mediated extracellular vesicle-VEGF-C secretion and pancreatic cancer metastasis.
2. 2020-Multi-omics and precision medicine joint conference, Chang Gung University, Taoyuan, Taiwan. Nov 14-15, 2020. Section III. Title: The function and regulation of EV-VEGF-C in pancreatic cancer early metastasis.
3. 2020-TSEV symposium Taipei, Taiwan. Jun 22, 2020. Title: Targeting DUSP2-mediated EV-VEGF-C secretion ameliorates pancreatic cancer early dissemination.
4. 2019-APSEV 2019 Inaugural Annual Meeting & KSEV 2019 Annual Meeting, Jeju, Republic of Korea. Nov 25-26, 2019. Plenary Session 3. Title: Regulation of EV-VEGF-C secretion by DUSP2 in mediating pancreatic cancer early dissemination.
5. 2017-The 10<sup>th</sup> International Pancreatic Cancer Conference, Commemorative Lecture of Pin-Wen Lin and 2017 Cancer Biology Symposium. Tainan, Taiwan. Jun 23-25, 2017. Session 3: Tumor Microenvironment of Pancreatic Cancer. Title: The novel function of DUSP2/VEGF-C axis in

pancreatic cancer progression.

6. 2013-AACR Advances in Breast Cancer Research, San Diego, CA, October 3-6, 2013. Session 4: Tumor Dormancy and Metastasis. Title: The Six2 homeoprotein mediates breast cancer metastasis via repressing E-cadherin

### **Scientific meeting**

1. 2018-7<sup>th</sup> Asian Conference of Endometriosis, Taipei, Taiwan. Sept 14-16, 2018 (section moderator)
2. 2018-EACR25 25<sup>th</sup> Biennial Congress of the European Association for Cancer Research, Amsterdam, Netherlands. Jun 30-July 3, 2018
3. 2013-AACR Annual Meeting 2013 Washington, DC, April 6-10 (poster was featured by AACR news release of the University of Colorado Cancer Center)
4. 2011-Department of Defense Era of Hope Meeting, Orlando, Florida, August 2-5, 2011
5. 2011-102nd AACR Annual Meeting 2011 in Orlando, Florida, April 2-6, 2011
6. 2010- Joint MRS-AACR Conference on Metastasis and the Tumor Microenvironment, Philadelphia, Pennsylvania, September 12-15, 2010
7. 2009-AACR 100<sup>th</sup> annual meeting, Denver, Colorado
8. 2004-37<sup>th</sup> Annual meetings of Society for the Study of Reproduction, Vancouver, Canada (oral presentation)
9. 2003-19<sup>th</sup> Conference of the Taiwan Society Biochemistry and Molecular Biology, Taipei, Taiwan
10. 2003-9<sup>th</sup> Taiwan-Hong Kong Physiology Symposium in the University Of Hong Kong, Hong Kong

### **Award and Grant**

1. 2021- Outstanding Paper Award of the 31st Wang Ming-Ning Memorial Foundation Award
2. 08/01/2017-07/31/2020-independent research grant from Ministry of Sciences and Technology (106-2321-B-006 -022 -MY3)- success rates <5%
3. 08/01/2014-07/31/2017-independent postdoctoral grant from Ministry of Sciences and Technology (103-2321-B-006-020-MY3)- success rates <5%
4. 07/01/2013-06/30/2014- research grant from the Cancer League of Colorado.
5. 2013-AACR-Aflac, Incorporated Scholar-in-Training Awards, 2013 AACR Advances in Breast Cancer Research
6. 01/01/2010-12/31/2012- predoctoral fellowship from the Department of Defense Breast Cancer Research Program (W81ZWH-10-1-0162)